Latest California Healthline Stories
‘An Arm and a Leg’: The New Cap on Medicare Drug Costs
In this episode, Julie Rovner, chief Washington correspondent for KHN, guides listeners through decades of dealings between Congress and Big Pharma.
Did the US Jump the Gun With the New Omicron-Targeted Vaccines?
With fears of a winter surge looming, government agencies have authorized and encouraged vaccination with a newly formulated booster. But the science to support that decision remains inconclusive.
Readers and Tweeters Place Value on Community Services and Life-Sustaining Care
KHN gives readers a chance to comment on a recent batch of stories.
Journalists Scrutinize Retail Giants’ Push Into Health Care and Government’s HIV Surveillance
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Big Pharma Went All In to Kill Drug Pricing Negotiations
For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasn’t materialized.
No, the Senate-Passed Reconciliation Bill Won’t Strip $300 Billion From Medicare
Under the Medicare drug negotiations provisions in the reconciliation bill, the federal government would see its outlays reduced by about $300 billion. That reduction wouldn’t result from cuts in benefits. Instead, Medicare would be empowered to leverage its market power to pay lower prices for certain drugs.
A GOP Talking Point Suggests Birth Control Is Not at Risk. Evidence Suggests Otherwise.
Republicans say Democrats are wrong to claim that birth control could be the Supreme Court’s next target. But Democrats have plenty of evidence that it might be.
Watch: The Nitty-Gritty of Medicare Drug Price Negotiations — And Patients’ Potential Savings
KHN chief Washington correspondent Julie Rovner discusses the Senate Democrats’ plans to let Medicare negotiate some drug prices, cap out-of-pocket drug costs for seniors, and fund enhanced subsides for ACA marketplace health plans.
Lo que debes saber sobre Paxlovid para tratar covid, en especial, ¿debes tomarlo?
Desde que Paxlovid comenzó a estar disponible hace siete meses, ha eclipsado otras terapias disponibles para prevenir los síntomas graves de covid en pacientes de alto riesgo. Algunos médicos se apresuran a recetarlo, pero como ocurre con tanto sobre la pandemia de covid, hay controversia.
Everything You Need to Know About Paxlovid — Especially, Should You Take It?
Paxlovid has eclipsed other available therapies for preventing life-threatening covid symptoms in high-risk patients. But even as doctors praise its effectiveness, many say they have unanswered questions about prescribing the drug and want more and better data about it.